What is Tay-Sachs Disease?
Tay-Sachs Diseaseor GM2 Gangliosidosis is an autosomal recessive metabolic disorder due to β-hexosaminidase deficiency. It is a group of lysosomal lipid storage disorders and is caused by mutations in at least 1 of 3 recessive genes: HEXA (Tays–Sachs disease, where only the isoform A is deficient), HEXB (Sandhoff disease, where both isoforms are involved), and GM2A (an activator required for both isoforms activity). Normal products of all 3 genes are required for normal catabolism of the GM2 ganglioside substrate. Deficient activity of these enzymes leads to accumulation of the substrate inside neuronal lysosomes, leading to cell death. These disorders cause a progressive deterioration of nerve cells and inherited deficiency in creating hexosaminidases A, B, and AB.
Tay-Sachs Disease Epidemiology
· The incidence of Tay-Sachs Disease in general population has been approximated to be 1 in 112,000 live births, which represents the prevalence to be 1 in 3900.
· Tay-Sachs Disease affects both males and females equally.
How will Tay-Sachs Disease Market change in the forecast period?
According to DelveInsight, Tay-Sachs Disease market in 7MM is expected to change in the study period 2017-2030.
The Tay-Sachs Disease market report provides current treatment practices, emerging drugs, Tay-Sachs Disease market share of the individual therapies, current and forecasted Tay-Sachs Disease market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Tay-Sachs Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
The Tay-Sachs Disease market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Tay-Sachs Disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Tay-Sachs Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.